• All sections
  • C - Chemistrymetallurgy
  • C07D - Heterocyclic compounds
  • C07D 263/34 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Patent holdings for IPC class C07D 263/34

Total number of patents in this class: 258

10-year publication summary

23
15
21
16
18
15
16
20
13
9
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

Principal owners for this class

Owner
All patents
This class
Theravance Biopharma R&D IP, LLC
458
27
Pro Farm Group, Inc.
119
10
DSM IP Assets B.V.
5591
8
Siemens Medical Solutions USA, Inc.
1515
7
Astellas Pharma Inc.
1088
6
Boehringer Ingelheim International GmbH
4650
5
Takeda Pharmaceutical Company Limited
2713
5
Nippon Shinyaku Co., Ltd.
325
5
Arizona Board of Regents on behalf of Arizona State University
2625
4
Blade Therapeutics, Inc.
19
4
Kissei Pharmaceutical Co., Ltd.
183
4
Otsuka Pharmaceutical Co., Ltd.
1493
4
AstraZeneca AB
2909
3
Janssen Pharmaceutica N.V.
3392
3
Merck Patent GmbH
5831
3
Syngenta Crop Protection AG
6054
3
Allergan, Inc.
2349
3
Bayer Pharma AG
1052
3
Amgen Inc.
4074
3
Beiersdorf AG
3014
3
Other owners 145